News | September 04, 2025
Syntegon reports H1 2025 EBITDA higher by 41% to €127 million
Free cash flow also reached €63 million, representing an 11 percent increase compared to the high benchmark set in 2024
Free cash flow also reached €63 million, representing an 11 percent increase compared to the high benchmark set in 2024
Brenntag Specialties will provide pharmaceutical manufacturers and biopharmaceutical companies with a reliable supply of high-purity, GMP-compliant acetates
Enlicitide achieved all primary and key secondary endpoints, demonstrating statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol
The three-day expo will feature an expansive exhibition showcasing MSMEs, startups, research institutions, future innovation pavilions, state showcases, and government initiatives
It offers clear environmental benefits, lower emissions, reduced hazardous material use, and alignment with circular economy goals
The trial is the largest to date evaluating Leqvio and the first to focus on patient-centered outcomes
Glenmark’s Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials is bioequivalent and therapeutically equivalent to the reference listed drug, Halaven Injection, 1 mg/2 mL (0.5 mg/mL),of Eisai
Fortis will assume complete operational and financial control, allowing it to consolidate the hospital's performance within its network
Facility designed to advance the next generation of imaging systems
Government policies and competitive industry driving India’s MedTech sector for sustained double-digit growth
Subscribe To Our Newsletter & Stay Updated
